Journal of Infectious Diseases and Medical Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Journal of Infectious Diseases and Medical Microbiology (2022) Volume 6, Issue 5

Secondary Bacterial Infections During Pulmonary Viral Disease

Harry Ben*

Department of Microbiology, University of Queensland, Australia

*Corresponding Author:
Harry Ben
Department of Microbiology
University of Queensland, Australia

Received: 29-Aug-2022, Manuscript No. AAJIDMM-22-77880; Editor assigned: 01-Sep-2022, PreQC No. AAJIDMM -22-77880(PQ); Reviewed: 15-Sep-2022, QC No. AAJIDMM-22-77880; Revised: 17-Sep-2022, QC No. AAJIDMM -22-77880(R); Published: 24-Sep-2022, DOI: 10.35841/aajidmm-6.5.123

Citation: Ben H. Secondary bacterial infections during pulmonary viral disease. J Infect Dis Med Microbiol. 2022;6(5):123




The beyond too many years have visible the emergence of four severe viral outbreaks which includes the 2002 Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) epidemic, the 2009 influenza A H1N1 pandemic, 2012 Middle East Respiratory Syndrome (MERS) outbreak, and maximum these days the COVID-19 pandemic. Emergence of novel lethal CoV traces in human populations have become extra frequent and are of increasing global issue; SARS-CoV-2, a novel CoV that precipitated a primary important outbreak in China in 2019 has now infected nearly 8 million human beings globally and resulted in 434,000 deaths (as of June 15, 2020), a far greater sickness burden than SARS and MERS At least one in seven COVID-19 sufferers turned into determined to be additionally inflamed with a secondary bacterial infection with 50% of the fatalities in the course of the SARS-CoV-2 epidemic caused by untreated or untreatable secondary bacterial infections, in maximum cases in the lung. While antibiotics do no longer have impact at the virus itself, almost all significantly sick patients are handled with antibiotics to try to prevent the prevalence of secondary bacterial infections. Any surge in antibiotic use throughout the COVID-19 pandemic will have a unfavourable effect on antibiotic resistance charges for nosocomial bacterial pathogens, fueling global growth of antibiotic resistant bacterial pathogens [1].

Secondary bacterial infections expand in patients for the duration of or after initial contamination with an infective pathogen, often a virulent disease and are associated with high morbidity and mortality fee. There are numerous hypotheses why secondary infections fast establish in patients with a pulmonary viral contamination, along with immunological host modifications, mechanical damage and diffusion, and elimination of mucus inside the lungs. Much of how secondary infections occur themselves and what function the immune reaction to a virulent disease impacts the protection towards a prokaryotic pathogen, is poorly understood. Polymicrobial, viral–bacterial co-infections can broaden as a result of an altered immune response blended with on hand routes of access for the bacterial pathogens.

There are few reviews detailing secondary bacterial infections or even less describing AMR. Until a vaccine is deployed globally, bacterial secondary infections will remain essential in COVID-19 clinical care. New antibiotics or alternative treatments focused against secondary bacterial infections want to be advanced for COVID-19 and next pandemics. With the looming crisis of growing numbers of MDR bacterial infections, options to chemical antibiotics are urgently needed. To save you secondary bacterial infections, prophylactic use of phages may be implemented similar to small-molecule broadband antibiotics. This might require a “phage cocktail” that goals a vast range of pathogenic species likely to cause bacterial pneumonia. Since phages are rather precise, a phage cocktail might want to comprise a diffusion of phages. Regulatory suggestions for the medical utility of phages aren't (completely) established in most nations; each component of a therapeutic calls for to be accredited, making deployment of phages as prophylactics in patients inflamed with pulmonary viruses, complex. Phage-derived healing proteins including endolysins could be tremendous as they would have a lower specificity towards micro-organism and be able to inactivate a broader variety of bacterial pathogens [2,5].


The ability for utility of phage merchandise, such as endolysins, must be investigated. Pulmonary CoVs will probably be a scientific assignment for many years to come. Viral pandemics from CoVs and emerging pathogens are inevitable in our globalized global with interconnected societies, travel, and trade. We require to be properly organized for long-time period management of COVID-19 and for the following pandemic, exploring and setting up new avenues to treat bacterial pathogens commonly observed in secondary infections.


  1. Ahmadi M, Karimi Torshizi MA, Rahimi S, et al. Prophylactic bacteriophage administration more effective than post-infection administration in reducing Salmonella enterica serovar Enteritidis shedding in quail. Frontiers in microbiology. 2016;7:1253.
  2. Indexed at, Google Scholar, Cross Ref

  3. Akturk E, Oliveira H, Santos SB, et al. Synergistic action of phage and antibiotics: parameters to enhance the killing efficacy against mono and dual-species biofilms. Antibiotics. 2019;8(3):103.
  4. Indexed at, Google Scholar, Cross Ref

  5. Borysowski J, Górski A. Is phage therapy acceptable in the immunocompromised host? International Journal of Infectious Diseases. 2008;12(5):466-71.
  6. Indexed at, Google Scholar, Cross Ref

  7. Briers Y, Lavigne R. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future microbiology. 2015;10(3):377-90.
  8. Indexed at, Google Scholar, Cross Ref

  9. Capparelli R, Parlato M, Borriello G, et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrobial agents and chemotherapy. 2007;51(8):2765-73.
  10. Indexed at, Google Scholar, Cross Ref

Get the App